By Joan Boren2023-12-07T00:00:00
The session opened with an overview of the European regulatory pathways for medicinal products and medical devices (MD)/ in vitro diagnostics (IVDs) by Stiina Aarum. While the EMA reviews the marketing authorisation for a medicinal product, MD/IVD are assessed by a notified body (NB) of choice. For medicines used in combination with a MD, the EMA will assess safety and efficacy of the medicine used in combination with the device as part of the marketing authorisation application (MAA).
Register to continue to access industry news, podcasts and commentary plus one member-only journal article each month. You will still be able to view editorials and contents pages without restriction.
Already a TOPRA member?
Using your MyTOPRA credentials, log-in now for unlimited access to all Regulatory Rapporteur journal articles, online archive and the latest industry news and content.
LoginBecome a TOPRA member and join our global regulatory affairs community.
The peer-reviewed journal, published 11 times per year and available free to TOPRA members.
The Organisation for Professionals in Regulatory Affairs
TOPRA office
TOPRA Publishing, 6th Floor, 3 Harbour Exchange, South Quay, London E14 9GE, UK
Tel: +44 (0) 20 7510 2560
Email: publications@topra.org
TOPRA AISBL
Blvd du Souverain 280, 1160 Brussels, Belgium
Tel: +32 (0) 2 808 72 70
Site powered by Webvision Cloud